Evidence map›Paper›PMID 37925183›Full record

ArticleMethods in enzymology2023

Methods for the study of ribonuclease targeting chimeras (RiboTACs).

Noah A Springer, Samantha M Meyer, Amirhossein Taghavi, Raphael I Benhamou, Yuquan Tong, Jessica L Childs-Disney, Matthew D Disney

Open access · greenAbstract read
In one paragraph

Article in Methods in enzymology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. RNA Splicing as a Therapeutic Target in Cancer.Annual review of pharmacology and toxicology · 2026
    Review
  3. [Targeting chimera technology: A new tool for undruggable in breast cancer].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Noah A SpringerThe Scripps Research Institute & The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Department of Chemistry, Scripps Way, Jupiter, FL, United States.
Samantha M MeyerThe Scripps Research Institute & The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Department of Chemistry, Scripps Way, Jupiter, FL, United States.
Amirhossein TaghaviThe Scripps Research Institute & The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Department of Chemistry, Scripps Way, Jupiter, FL, United States.
Raphael I BenhamouInstitute for Drug Research, The School of Pharmacy, The Hebrew University of Jerusalem, Hadassah-Ein Kerem, Jerusalem, Israel.
Yuquan TongThe Scripps Research Institute & The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Department of Chemistry, Scripps Way, Jupiter, FL, United States.
Jessica L Childs-DisneyThe Scripps Research Institute & The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Department of Chemistry, Scripps Way, Jupiter, FL, United States.
Matthew D DisneyThe Scripps Research Institute & The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Department of Chemistry, Scripps Way, Jupiter, FL, United States. Electronic address: mdisney@ufl.edu.
Scripps Research Institute · USThe Herbert Wertheim UF Scripps Institute for Biomedical Innovation & TechnologyHebrew University of Jerusalem · IL

Funding

Design of Precision Small Molecules Targeting RNA Repeating Transcripts to Manipulate and Study Disease BiologyR35NS116846 · NINDS · UNIVERSITY OF FLORIDA · PI Matthew D Disney · 2020 to 2026
$9.4M
Targeted degradation of RNAs by using small moleculesR01CA249180 · NCI · UNIVERSITY OF FLORIDA · PI Matthew D Disney · 2020 to 2026
$4.8M
NCI NIH HHS R01 CA249180NINDS NIH HHS R35 NS116846
6 · The paper itself

Abstract

Recently, a class of heterobifunctional small molecules called ribonuclease targeting chimeras (RiboTACs) have been developed that selectively induce degradation of RNAs in cells. These molecules function by recruiting latent ribonuclease (RNase L), an endoribonuclease involved in the innate immune response, to targeted RNA structures. The RiboTACs must activate RNase L in proximity to the RNA, resulting in cleavage of the RNA and downstream degradation. To develop and validate a new RiboTAC, several steps must be taken. First, small molecule activators that bind to RNase L must be identified. Next, since RNase L is only catalytically active upon ligand-induced homodimerization, the capability of identified small molecules to activate RNase L must be assessed. RNase L-activating small molecules should then be coupled to validated RNA-binding small molecules to construct the active RiboTAC. This RiboTAC can finally be assessed in cells for RNase L-dependent degradation of target RNAs. This chapter will provide several methods that are helpful to develop and assess RiboTACs throughout this process, including recombinant RNase L expression, methods to assess RNase L engagement in vitro such as saturation transfer difference nuclear magnetic resonance (STD NMR), an in vitro assay to assess activation of RNase L, and cellular methods to demonstrate RNase L-dependent cleavage.

Indexed as

EndoribonucleasesRibonucleasesImmunity, InnateRNAEndoribonucleasesRibonucleasesRNAInduced proximityRibonuclease targeting chimeras (RiboTACs)RNARNaseTargeted degradation

Identifiers

PMID37925183
PMCPMC10763923
OpenAlexW4386647279

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.